行情

LPTX

LPTX

LEAP THERAPEUTIC
NASDAQ

实时行情|Nasdaq Last Sale

0.8000
+0.0019
+0.23%
交易中 12:22 12/10 EST
开盘
0.8000
昨收
0.7981
最高
0.8000
最低
0.7760
成交量
3.93万
成交额
--
52周最高
3.553
52周最低
0.5728
市值
1,935.59万
市盈率(TTM)
-0.7532
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

LPTX 新闻

  • 报告:6家硅谷巨头过去10年全球避税1000亿美元
  • 新浪科技.12/03 10:17
  • 报告:秘鲁2019年三季度倒闭公司数量同比增五成
  • 中国新闻网.12/03 10:16
  • 英国保守党支持率较工党的领先优势扩大至12个百分点
  • 新浪财经综合.12/03 10:15
  • 拼多多无证经营支付踩雷区 上海央行正督促其整改
  • 21世纪经济报道.12/03 09:56

更多

所属板块

生物技术和医学研究
+0.65%
制药与医学研究
+0.69%

热门股票

名称
价格
涨跌幅

LPTX 简况

Leap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer, cholangiocarcinoma, non-small cell lung cancer, and other tumor types, such as pancreatic, gastric, liver, head and neck, uterine, and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. .
展开

Webull提供Leap Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。